Singaporean cell therapy biotech with off-the-shelf ambitions wraps modest IPO
Almost five months after first filing for an IPO, a small Singaporean cell therapy biotech is landing on the Nasdaq.
CytoMed Therapeutics managed to raise slightly more than $9.6 million by pricing its stock at $4 per share. It’s not a large sum, especially for a company whose ambition is to develop off-the-shelf cell therapies for cancer, but it does substantially boost CytoMed’s reserves — which it counted at around $1.07 million as of last June.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
